Avalon GloboCare Partners With Qi Diagnostics To Co-Develop International Multi-Center Clinical Studies For DKAir Breathalyzer Device For The Early Detection Of Diabetic Ketoacidosis
Portfolio Pulse from Benzinga Newsdesk
Avalon GloboCare has partnered with Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir Breathalyzer device, aimed at early detection of Diabetic Ketoacidosis.
October 18, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avalon GloboCare's partnership with Qi Diagnostics for the development of the DKAir Breathalyzer device could potentially boost its product portfolio and market presence.
The partnership with Qi Diagnostics allows Avalon GloboCare to co-develop a potentially groundbreaking device for early detection of Diabetic Ketoacidosis. This could enhance Avalon's product portfolio and increase its market presence, potentially leading to increased revenues and a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100